.Attribute Medication, Posted online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) treatment of people with HER2+ enhanced bosom cancer and also active or even steady brain metastases showed constant intracranial activity and also systemic efficacy of T-DXd.